Expression of TAU in insulin-secreting cells and its interaction with the calcium-binding protein secretagogin

Journal of Endocrinology

Volumn 205, Issue 1, 2010, Pages 25-36

  Maj, Magdalena ^a   Gartner, Wolfgang ^a,c   Ilhan, Aysegul ^a   Neziri, Dashurie ^a   Attems, Johannes ^b   Wagner, Ludwig ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c St Vincent Hospital   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; INSULIN; ISOPROTEIN; SECRETAGOGIN; SUCROSE; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASSAY; BRAIN; CELL CLONE; CELL LINE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DATA BASE; FRACTIONATION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INSULINOMA; LANGERHANS CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; SUCROSE DENSITY GRADIENT CENTRIFUGATION; TAUOPATHY; TUMOR CELL;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; INSULIN-SECRETING CELLS; INSULINOMA; ISLETS OF LANGERHANS; PANCREATIC NEOPLASMS; PROTEIN ISOFORMS; RATS; TAU PROTEINS;

EID: 77949500684     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-09-0341     Document Type: Article

References (42)

1. Albrektsen T, Richter HE, Clausen JT & Fleckner J 2001 Identification of a novel integral plasma membrane protein induced during adipocyte differentiation. Biochemical Journal 359 393-402.
2. Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I & Iqbal K 2001 Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. Journal of Biological Chemistry 276 37967-37973.
3. Attems J, Quass M, Gartner W, Nabokikh A, Wagner L, Steurer S, Arbes S, Lintner F & Jellinger K 2007 Immunoreactivity of calcium binding protein secretagogin in the human hippocampus is restricted to pyramidal neurons. Experimental Gerontology 42 215-222.
4. Attems J, Preusser M, Grosinger-Quass M,Wagner L, Lintner F & Jellinger K 2008 Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer's disease. Neuropathology and Applied Neurobiology 34 23-32.
5. Birkenkamp-Demtroder K, Wagner L, Brandt Sorensen F, Bording Astrup L, Gartner W, Scherubl H, Heine B, Christiansen P & Orntoft TF 2005 Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology 82 121-138.
6. Boyne LJ, Tessler A, Murray M & Fischer I 1995 Distribution of big tau in the central nervous system of the adult and developing rat. Journal of Comparative Neurology 358 279-293.
7. Cras-Meneur C, Inoue H, Zhou Y, Ohsugi M, Bernal-Mizrachi E, Pape D, Clifton SW & Permutt MA 2004 An expression profile of human pancreatic islet mRNAs by serial analysis of gene expression (SAGE). Diabetologia 47 284-299.
8. Delacourte A & Defossez A 1986 Alzheimer's disease: tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. Journal of Neurological Sciences 76 173-186.
9. Dias WB & Hart GW 2007 O-GlcNAc modification in diabetes and Alzheimer's disease. Molecular BioSystems 3 766-772.
10. Gartner W, Lang W, Leutmetzer F, Domanovits H, Waldhausl W & Wagner L 2001 Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2C)-binding protein. Cerebral Cortex 11 1161-1169.
11. Gartner W, Vila G, Daneva T, Nabokikh A, Koc-Saral F, Ilhan A, Majdic O, Luger A & Wagner L 2007 New functional aspects of the neuroendocrine marker secretagogin based on the characterization of its rat homolog. American Journal of Physiology. Endocrinology and Metabolism 293 E347-E354.
12. 2+ as evidences in single pancreatic islets. Journal of Biological Chemistry 268 22265-22268.
13. Goedert M & Jakes R 1990 Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO Journal 9 4225-4230.
14. Goedert M & Spillantini MG 2006 A century of Alzheimer's disease. Science 314 777-781.
15. Goedert M, Wischik CM, Crowther RA,Walker JE & Klug A 1988 Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. PNAS 85 4051-4055.
16. Greenberg SG & Davies P 1990 A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. PNAS 87 5827-5831.
17. Greene JR, Radenahmad N, Wilcock GK, Neal JW & Pearson RC 2001 Accumulation of calbindin in cortical pyramidal cells with ageing; a putative protective mechanism which fails in Alzheimer's disease. Neuropathology and Applied Neurobiology 27 339-342.
18. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM& Binder LI 1986 Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. PNAS 83 4913-4917.
19. Hof PR, Nimchinsky EA, Celio MR, Bouras C & Morrison JH 1993 Calretinin-immunoreactive neocortical interneurons are unaffected in Alzheimer's disease. Neuroscience Letters 152 145-148.
20. Janson J, Ashley RH, Harrison D, McIntyre S & Butler PC 1999 The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48 491-498.
21. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC & Butler PC 2004 Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53 474-481.
22. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E & Mandelkow EM 2006 Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. Journal of Biological Chemistry 281 1205-1214.
23. Kosik KS, Joachim CL & Selkoe DJ 1986 Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. PNAS 83 4044-4048.
24. Ksiezak-Reding H, Morgan K & Dickson DW 1994 Tau immunoreactivity and SDS solubility of two populations of paired helical filaments that differ in morphology. Brain Research 649 185-196.
25. Lai M, Lu B, Xing X, Xu E, Ren G & Huang Q 2006 Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A. Virchows Archiv 449 402-409.
26. LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI & Brady ST 2009 The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. Journal of Neuroscience Research 87 440-451.
27. Levy SF, Leboeuf AC,Massie MR, Jordan MA, Wilson L & Feinstein SC 2005 Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners. Implications for neurodegeneration. Journal of Biological Chemistry 280 13520-13528.
28. Lorenzo A, Razzaboni B, Weir GC & Yankner BA 1994 Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368 756-760.
29. Miklossy J, Taddei K, Martins R, Escher G, Kraftsik R, Pillevuit O, Lepori D & Campiche M 1999 Alzheimer disease: curly fibers and tangles in organs other than brain. Journal of Neuropathology and Experimental Neurology 58 803-814.
30. Miklossy J, Qing H, Radenovic A, Kis A, Vileno B, Laszlo F, Miller L, Martins RN, Waeber G, Mooser V et al. 2008 Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiology of Aging. DOI: 10.1016/j.neurobiolaging.2008.08.019.
31. O'Brien TD, Butler PC, Kreutter DK, Kane LA & Eberhardt NL 1995 Human islet amyloid polypeptide expression in COS-1 cells. A model of intracellular amyloidogenesis. American Journal of Pathology 147 609-616.
32. O'Rahilly S, Turner RC &Matthews DR 1988 Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. New England Journal of Medicine 318 1225-1230.
33. Probst A, Gotz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL, Hong M, Ishihara T, Lee VM, Trojanowski JQ et al. 2000 Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathologica 99 469-481.
34. Ristow M 2004 Neurodegenerative disorders associated with diabetes mellitus. Journal of Molecular Medicine 82 510-529.
35. Rogstam A, Linse S, Lindqvist A, James P, Wagner L & Berggard T 2007 Binding of calcium ions and SNAP-25 to the hexa EF-hand protein secretagogin. Biochemical Journal 401 353-363.
36. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E et al. 2005 Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 476-481.
37. Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y & Kimura H 1995 Amyloid peptides are toxic via a common oxidative mechanism. PNAS 92 1989-1993.
38. Simpson IA, Yver DR, Hissin PJ, Wardzala LJ, Karnieli E, Salans LB & Cushman SW 1983 Insulin-stimulated translocation of glucose transporters in the isolated rat adipose cells: characterization of subcellular fractions. Biochimica et Biophysica Acta 763 393-407.
39. Taleghany N & Oblinger MM 1992 Regional distribution and biochemical characteristics of high molecular weight tau in the nervous system. Journal of Neuroscience Research 33 257-265.
40. Tischler AS 2002 Chromaffin cells as models of endocrine cells and neurons. Annals of the New York Academy of Sciences 971 366-370.
41. Vega IE, Traverso EE, Ferrer-Acosta Y, Matos E, Colon M, Gonzalez J, Dickson D, Hutton M, Lewis J & Yen SH 2008 A novel calcium-binding protein is associated with tau proteins in tauopathy. Journal of Neurochemistry 106 96-106.
42. 2+-binding protein. Journal of Biological Chemistry 275 24740-24751.